Variantyx snags $20m Series C

Variantyx, a provider of a genome sequencing-based testing program that diagnoses genetic disorders, has secured $20 million in Series C funding.

15 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles